Close Menu

Microarrays & Multiplexing

News on microarrays, multiplexing, genotyping, cytogenetics, gene expression profiling in genetics, genomics, and molecular diagnostics.

Genome-wide association studies offer a look at the rare and common contributors to the heart condition, pointing to possible prediction and treatment tools.

By uncovering genetic factors behind blood and urine biomarkers, researchers came up with polygenic scores related to biomarker status and related disease risk.

Agilent said its qualitative assay is used for the postnatal diagnosis of copy-number alterations and copy-neutral loss of heterozygosity from DNA.

Boston-based NanoView aims to use its ExoView platform to understand the biological role of extracellular vesicles and their use as disease biomarkers.

The agreement will allow life science researchers in Switzerland better access to the image-based CellRaft AIR system's instrument, consumables, and support.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.

Jan
26
Sponsored by
LGC, Biosearch Technologies

Reduced representation next-generation sequencing (NGS) methods are driving understanding of both physical and structural variation in all species.

Feb
18
Sponsored by
BD

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression. 

Feb
25
Sponsored by
Foundation Medicine

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.